Drug Type Recombinant polypeptide |
Synonyms OM 301, OM301 |
Target |
Action inhibitors |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteosarcoma | Preclinical | United States | 04 Jan 2024 | |
Acute Myeloid Leukemia | Preclinical | United States | 18 Aug 2022 | |
Multiple Myeloma | Preclinical | United States | 18 Aug 2022 | |
Solid tumor | Discovery | United States | 18 Aug 2022 |